Details of Disease

General Information of Disease (ID: DISY6744)

• Disease Name: Endometrium adenocarcinoma
• Synonyms: endometrial endometrioid adenocarcinoma; endometrioid carcinoma of endometrium; adenocarcinoma of the endometrium; endometrioid adenomas and carcinomas (morphologic abnormality); adenocarcinoma, endometrial, malignant; endometrioid adenoma or carcinoma; endometrium adenocarcinoma; endometrioid adenomas and carcinomas; endometrioid adenoma or carcinoma NOS (morphologic abnormality); adenocarcinoma of endometrium; adenocarcinoma of uterus; endometrial adenocarcinoma; endometrial adenoacanthoma; endometrial endometrioid adenocarcinoma with squamous differentiation
• Definition: An adenocarcinoma arising from the uterine body cavity. This is the most frequent malignant tumor affecting the uterine body, and is linked to estrogen therapy. Most patients present with uterine bleeding and are over age 40 at the time of diagnosis. The prognosis depends on the stage of the tumor, the depth of the uterine wall invasion, and the histologic subtype. Endometrioid adenocarcinoma is the most frequently seen morphologic variant of endometrial adenocarcinoma.
• Disease Hierarchy:
  DIS3IHTY: Adenocarcinoma
  DISXR5CY: Endometrial carcinoma
  DISY6744: Endometrium adenocarcinoma
• Disease Identifiers:
  MONDO ID: MONDO_0005461
  UMLS CUI: C1153706
  MedGen ID: 218862
  SNOMED CT ID: 123845008

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 16 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
CA12	TTSYM0R	Limited	Altered Expression	[1]
HSD17B1	TTIWB6L	Limited	Altered Expression	[2]
IRF1	TT4TU3L	Limited	Biomarker	[3]
RRM2	TT1S4LJ	Limited	Biomarker	[4]
STOML2	TTOI329	Limited	Altered Expression	[5]
FGFR2	TTGJVQM	moderate	Genetic Variation	[6]
PGF	TT48I1Y	moderate	Altered Expression	[7]
ACVR2B	TTLFRKS	Strong	Biomarker	[8]
AKT1	TTWTSCV	Strong	Biomarker	[9]
G6PC	TTBQMJ8	Strong	Biomarker	[10]
HOXA11	TTEX4ZA	Strong	Posttranslational Modification	[11]
IGFBP1	TTCJTWF	Strong	Altered Expression	[12]
PGR	TTUV8G9	Strong	Genetic Variation	[13]
PPIB	TT6ZFQ4	Strong	Biomarker	[14]
PPME1	TTXQ54R	Strong	Altered Expression	[15]
TSG101	TTHU7JA	Strong	Biomarker	[16]

This Disease Is Related to 32 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
GPX3	OT6PK94R	Limited	Biomarker	[17]
KCNH6	OTQ52G7V	Limited	Biomarker	[18]
SYTL2	OTUIOWKL	Limited	Altered Expression	[5]
LRIG2	OTDUBLIH	Disputed	Biomarker	[19]
CD109	OTDADBM4	moderate	Altered Expression	[20]
INHA	OT7HWCO3	moderate	Altered Expression	[21]
CDC42SE2	OT8SG9I1	Strong	Biomarker	[22]
CRABP1	OTISDG5X	Strong	Altered Expression	[23]
DAP	OT5YLL7E	Strong	Biomarker	[24]
DUSP6	OT4H6RKW	Strong	Biomarker	[25]
EBAG9	OTTQLQCP	Strong	Biomarker	[26]
ERRFI1	OT7VZ2IZ	Strong	Biomarker	[27]
FGF3	OT9PK2SI	Strong	Biomarker	[28]
FOXL2	OTFRQUYL	Strong	Genetic Variation	[6]
HMGN5	OTUUAHVQ	Strong	Altered Expression	[29]
HOXA10	OTB6GQ09	Strong	Altered Expression	[30]
INHBC	OT8SUTZR	Strong	Biomarker	[31]
INTS2	OT2N5TCK	Strong	Biomarker	[28]
KLF9	OTBFEJRQ	Strong	Biomarker	[32]
LARP6	OTUQ9QS9	Strong	Biomarker	[33]
LSR	OTR8Y32X	Strong	Altered Expression	[34]
MUC6	OTPVL723	Strong	Altered Expression	[35]
NDC80	OTS7D306	Strong	Biomarker	[33]
NEURL1	OT2C4P70	Strong	Biomarker	[36]
PRB1	OTV0SYMD	Strong	Biomarker	[37]
RACGAP1	OTQE8IEH	Strong	Altered Expression	[38]
RHOC	OTOLE1FT	Strong	Altered Expression	[39]
RPL36A	OT1LYV85	Strong	Biomarker	[27]
SLIT3	OTU8MKEU	Strong	Altered Expression	[40]
SPRY4	OT2VK9N0	Strong	Biomarker	[41]
TCFL5	OTJL4348	Strong	Genetic Variation	[42]
THEMIS2	OTI1OBLN	Strong	Altered Expression	[43]

References

• [1] Carbonic anhydrase isozymes II, IX, and XII in uterine tumors.APMIS. 2012 Feb;120(2):117-29. doi: 10.1111/j.1600-0463.2011.02820.x. Epub 2011 Oct 25.
• [2] Blocking 17-hydroxysteroid dehydrogenase type 1 in endometrial cancer: a potential novel endocrine therapeutic approach.J Pathol. 2018 Feb;244(2):203-214. doi: 10.1002/path.5004. Epub 2018 Jan 3.
• [3] Molecular classification of spontaneous endometrial adenocarcinomas in BDII rats.Endocr Relat Cancer. 2009 Mar;16(1):99-111. doi: 10.1677/ERC-08-0185. Epub 2008 Dec 15.
• [4] Oncogene amplification in the proximal part of chromosome 6 in rat endometrial adenocarcinoma as revealed by combined BAC/PAC FISH, chromosome painting, zoo-FISH, and allelotyping.Genes Chromosomes Cancer. 2005 Oct;44(2):139-53. doi: 10.1002/gcc.20220.
• [5] Stomatin-like protein 2 is overexpressed and related to cell growth in human endometrial adenocarcinoma.Oncol Rep. 2007 Apr;17(4):829-33.
• [6] Disparate genomic characteristics of concurrent endometrial adenocarcinoma and ovarian granulosa cell tumor, revealed by targeted next-generation sequencing.Pathol Res Pract. 2018 Aug;214(8):1231-1233. doi: 10.1016/j.prp.2018.06.009. Epub 2018 Jun 19.
• [7] Chemokine (C-C) motif ligand 20 is regulated by PGF(2)-F-prostanoid receptor signalling in endometrial adenocarcinoma and promotes cell proliferation.Mol Cell Endocrinol. 2011 Jan 1;331(1):129-35. doi: 10.1016/j.mce.2010.08.018. Epub 2010 Sep 15.
• [8] Deep Infiltrating Endometriosis and Endometrial Adenocarcinoma Express High Levels of Myostatin and Its Receptors Messenger RNAs.Reprod Sci. 2017 Dec;24(12):1577-1582. doi: 10.1177/1933719117698579. Epub 2017 Mar 27.
• [9] Nuclear PTEN Localization Contributes to DNA Damage Response in Endometrial Adenocarcinoma and Could Have a Diagnostic Benefit for Therapeutic Management of the Disease.Mol Cancer Ther. 2018 Sep;17(9):1995-2003. doi: 10.1158/1535-7163.MCT-17-1255. Epub 2018 Jun 13.
• [10] Association between 18F-fluorodeoxyglucose-PET/CT and histological grade of uterine endometrial carcinoma.Taiwan J Obstet Gynecol. 2018 Apr;57(2):283-288. doi: 10.1016/j.tjog.2018.02.018.
• [11] Frequent HOXA11 and THBS2 promoter methylation, and a methylator phenotype in endometrial adenocarcinoma.Clin Cancer Res. 2003 Jun;9(6):2277-87.
• [12] Activation of human insulin-like growth factor binding protein-1 gene promoter by a distal regulatory sequence in a human endometrial adenocarcinoma cell line.Mol Endocrinol. 1995 Oct;9(10):1405-12. doi: 10.1210/mend.9.10.8544848.
• [13] Activin-like kinase 5 (ALK5) inactivation in the mouse uterus results in metastatic endometrial carcinoma.Proc Natl Acad Sci U S A. 2019 Feb 26;116(9):3883-3892. doi: 10.1073/pnas.1806838116. Epub 2019 Jan 17.
• [14] Proteomic analysis in endometrial cancer and endometrial hyperplasia tissues by 2D-DIGE technique.J Gynecol Obstet Hum Reprod. 2020 Feb;49(2):101652. doi: 10.1016/j.jogoh.2019.101652. Epub 2019 Nov 26.
• [15] PME-1 modulates protein phosphatase 2A activity to promote the malignant phenotype of endometrial cancer cells.Cancer Res. 2014 Aug 15;74(16):4295-305. doi: 10.1158/0008-5472.CAN-13-3130. Epub 2014 Jun 13.
• [16] TSG101 expression in gynecological tumors: relationship to cyclin D1, cyclin E, p53 and p16 proteins.Cell Mol Biol (Noisy-le-grand). 2001 Nov;47(7):1187-93.
• [17] Gene expression profiling predicts a three-gene expression signature of endometrial adenocarcinoma in a rat model.Cancer Cell Int. 2009 May 8;9:12. doi: 10.1186/1475-2867-9-12.
• [18] Selective expression of HERG and Kv2 channels influences proliferation of uterine cancer cells.Int J Oncol. 2004 Jul;25(1):153-9.
• [19] LRIG2 is a growth suppressor of Hec-1A and Ishikawa endometrial adenocarcinoma cells by regulating PI3K/AKT- and EGFR-mediated apoptosis and cell-cycle.Oncogenesis. 2018 Jan 23;7(1):3. doi: 10.1038/s41389-017-0019-1.
• [20] CD109 expression in squamous cell carcinoma of the uterine cervix.Pathol Int. 2005 Apr;55(4):165-9. doi: 10.1111/j.1440-1827.2005.01807.x.
• [21] Inhibin alpha-subunit and the inhibin coreceptor betaglycan are downregulated in endometrial carcinoma.Eur J Endocrinol. 2005 Feb;152(2):277-84. doi: 10.1530/eje.1.01849.
• [22] Adenovirus-mediated expression of p53 or p21 in a papillary serous endometrial carcinoma cell line (SPEC-2) results in both growth inhibition and apoptotic cell death: potential application of gene therapy to endometrial cancer.Clin Cancer Res. 2000 Jan;6(1):278-84.
• [23] Retinoic acid receptors and retinoid binding proteins in endometrial adenocarcinoma: differential expression of cellular retinoid binding proteins in endometrioid tumours.Int J Cancer. 1995 Aug 22;64(4):253-63. doi: 10.1002/ijc.2910640408.
• [24] Impaired death-associated protein kinase-mediated survival signals in 5-fluorouracil-resistant human endometrial adenocarcinoma cells.Oncol Rep. 2012 Jul;28(1):330-6. doi: 10.3892/or.2012.1774. Epub 2012 Apr 23.
• [25] Dusp6 inhibits epithelial-mesenchymal transition in endometrial adenocarcinoma via ERK signaling pathway.Radiol Oncol. 2019 Sep 24;53(3):307-315. doi: 10.2478/raon-2019-0034.
• [26] A highly polymorphic CA repeat marker at the EBAG9/RCAS1 locus on 8q23 that detected frequent multiplication in breast cancer.Ann Hum Biol. 2002 Jul-Aug;29(4):457-60. doi: 10.1080/03014460110087762.
• [27] Mig-6 modulates uterine steroid hormone responsiveness and exhibits altered expression in endometrial disease.Proc Natl Acad Sci U S A. 2009 May 26;106(21):8677-82. doi: 10.1073/pnas.0903632106. Epub 2009 May 13.
• [28] Detection of c-erbB-2/neu and fibroblast growth factor-3/INT-2 but not epidermal growth factor receptor gene amplification in endometrial cancer by differential polymerase chain reaction.Cancer. 1995 Apr 15;75(8):2139-46. doi: 10.1002/1097-0142(19950415)75:8<2139::aid-cncr2820750817>3.0.co;2-6.
• [29] HMGN5: a potential oncogene in gliomas.J Neurooncol. 2011 Sep;104(3):729-36. doi: 10.1007/s11060-011-0558-9. Epub 2011 Mar 4.
• [30] HOXA10 expression in endometrial adenocarcinoma.Tumour Biol. 2004 Sep-Dec;25(5-6):264-9. doi: 10.1159/000081390.
• [31] The inhibin-C subunit is down-regulated, while inhibin-E is up-regulated by interferon-1a in Ishikawa carcinoma cell line.Arch Gynecol Obstet. 2013 Oct;288(4):883-8. doi: 10.1007/s00404-013-2848-2. Epub 2013 Apr 12.
• [32] Kruppel-like factor 9 is a negative regulator of ligand-dependent estrogen receptor alpha signaling in Ishikawa endometrial adenocarcinoma cells.Mol Endocrinol. 2007 Dec;21(12):2988-3001. doi: 10.1210/me.2007-0242. Epub 2007 Aug 23.
• [33] Synthesis and structure-activity studies on novel analogs of human growth hormone releasing hormone (GHRH) with enhanced inhibitory activities on tumor growth.Peptides. 2017 Mar;89:60-70. doi: 10.1016/j.peptides.2017.01.009. Epub 2017 Jan 24.
• [34] Downregulation of lipolysis-stimulated lipoprotein receptor promotes cell invasion via claudin-1-mediated matrix metalloproteinases in human endometrial cancer.Oncol Lett. 2017 Dec;14(6):6776-6782. doi: 10.3892/ol.2017.7038. Epub 2017 Sep 22.
• [35] Mucin genes (MUC2, MUC4, MUC5AC, and MUC6) detection in normal and pathological endometrial tissues.Int J Gynecol Pathol. 2007 Jan;26(1):61-5. doi: 10.1097/01.pgp.0000225837.32719.c1.
• [36] Estrogens and glucocorticoids induce the expression of c-erbB2/NEU receptor in Ishikawa human endometrial cells.Life Sci. 1997;61(11):1083-95. doi: 10.1016/s0024-3205(97)00617-6.
• [37] Clinicoprognostic significance of pRb1 pathway alterations in uterine endometrial adenocarcinoma.Cancer Genet Cytogenet. 2004 Oct 15;154(2):186-9. doi: 10.1016/j.cancergencyto.2004.05.016.
• [38] RNA-seq Identification of RACGAP1 as a Metastatic Driver in Uterine Carcinosarcoma.Clin Cancer Res. 2016 Sep 15;22(18):4676-86. doi: 10.1158/1078-0432.CCR-15-2116. Epub 2016 Apr 27.
• [39] MicroRNA-372 inhibits endometrial carcinoma development by targeting the expression of the Ras homolog gene family member C (RhoC).Oncotarget. 2016 Feb 9;7(6):6649-64. doi: 10.18632/oncotarget.6544.
• [40] Curcumin exhibits anti-tumor effect and attenuates cellular migration via Slit-2 mediated down-regulation of SDF-1 and CXCR4 in endometrial adenocarcinoma cells.J Nutr Biochem. 2017 Jun;44:60-70. doi: 10.1016/j.jnutbio.2016.12.021. Epub 2017 Mar 16.
• [41] SPRY4-mediated ERK1/2 signaling inhibition abolishes 17-estradiol-induced cell growth in endometrial adenocarcinoma cell.Gynecol Endocrinol. 2014 Aug;30(8):600-4. doi: 10.3109/09513590.2014.912264. Epub 2014 May 8.
• [42] Combined Oral Medroxyprogesterone/Levonorgestrel-Intrauterine System Treatment for Women With Grade 2 Stage IA Endometrial Cancer.Int J Gynecol Cancer. 2017 May;27(4):738-742. doi: 10.1097/IGC.0000000000000927.
• [43] Icb-1 Gene expression is elevated in human endometrial adenocarcinoma and is closely associated with HER2 expression.Cancer Invest. 2010 Nov;28(9):904-9. doi: 10.3109/07357907.2010.483511.